Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-19 4:30 pm Purchase | 2026-02-17 | 13G | Immunic, Inc. IMUX | Soleus Capital Master Fund, L.P. | 6,792,000 5.500% | 6,792,000 (New Position) | Filing History |
| 2026-02-12 5:02 pm Purchase | 2025-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 10,361,860 9.990% | 3,757,864 (+56.90%) | Filing History |
| 2026-02-12 5:01 pm Sale | 2025-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Soleus Capital Master Fund, L.P. | 212,710 0.200% | -7,929,790 (-97.39%) | Filing History |
| 2026-02-12 5:01 pm Sale | 2025-12-31 | 13G | Organogenesis Holdings Inc. ORGO | Soleus Capital Master Fund, L.P. | 9,985,951 7.900% | -2,498,925 (-20.02%) | Filing History |
| 2026-02-12 5:01 pm Sale | 2025-12-31 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 8,530,665 7.600% | -1,114,207 (-11.55%) | Filing History |
| 2026-02-03 4:41 pm Purchase | 2026-02-02 | 13G | Context Therapeutics Inc. CNTX | Soleus Capital Master Fund, L.P. | 4,776,398 5.200% | 4,776,398 (New Position) | Filing History |
| 2026-01-13 4:31 pm Purchase | 2026-01-12 | 13G | Biodesix, Inc. BDSX | Soleus Capital Master Fund, L.P. | 500,000 6.300% | 500,000 (New Position) | Filing History |
| 2025-11-07 4:00 pm Sale | 2025-09-30 | 13G | Mural Oncology plc MURA | Soleus Capital Master Fund, L.P. | 0 0.000% | -1,323,877 (Position Closed) | Filing History |
| 2025-11-07 4:00 pm Sale | 2025-09-30 | 13G | STAAR Surgical Company STAA | Soleus Capital Master Fund, L.P. | 500,000 1.000% | -2,062,893 (-80.49%) | Filing History |
| 2025-11-07 4:00 pm Purchase | 2025-09-30 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 9,644,872 8.600% | 2,740,570 (+39.69%) | Filing History |
| 2025-11-07 4:00 pm Sale | 2025-09-30 | 13G | Surmodics, Inc. SRDX | Soleus Capital Master Fund, L.P. | 0 0.000% | -739,060 (Position Closed) | Filing History |
| 2025-08-05 5:00 pm Sale | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | Soleus Capital Master Fund, L.P. | 2,185,000 4.700% | -140,000 (-6.02%) | Filing History |
| 2025-08-05 5:00 pm Sale | 2025-06-30 | 13G | Rigel Pharmaceuticals, Inc. RIGL | Soleus Capital Master Fund, L.P. | 658,145 3.700% | -472,534 (-41.79%) | Filing History |
| 2025-08-05 5:00 pm Purchase | 2025-06-30 | 13G | Mural Oncology plc MURA | Soleus Capital Master Fund, L.P. | 1,323,877 7.600% | 243,950 (+22.59%) | Filing History |
| 2025-08-05 5:00 pm Sale | 2025-06-30 | 13G | Praxis Precision Medicines, Inc. PRAX | Soleus Capital Master Fund, L.P. | 966,740 4.600% | -51,000 (-5.01%) | Filing History |
| 2025-08-05 5:00 pm Purchase | 2025-06-30 | 13G | NeuroPace, Inc. NPCE | Soleus Capital Master Fund, L.P. | 2,303,828 7.000% | 2,303,828 (New Position) | Filing History |
| 2025-08-05 5:00 pm Purchase | 2025-06-30 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 6,904,302 6.200% | 1,382,888 (+25.05%) | Filing History |
| 2025-07-21 4:30 pm Purchase | 2025-07-17 | 13D | ESSA Pharma Inc. EPIX | Soleus Capital Master Fund, L.P. | 4,362,026 9.800% | 2,100,000 (+92.84%) | Filing History |
| 2025-06-16 5:00 pm Purchase | 2025-06-13 | 13G | UroGen Pharma Ltd. URGN | Soleus Capital Master Fund, L.P. | 2,325,000 5.000% | 2,325,000 (New Position) | Filing History |
| 2025-05-02 5:00 pm Sale | 2025-03-31 | 13G | AxoGen, Inc. AXGN | Soleus Capital Master Fund, L.P. | 1,446,117 3.700% | -1,559,826 (-51.89%) | Filing History |